Physician

Collin Cuong Vu, M.D.

According to 2025 Medicare claims, Collin Vu, M.D. (NPI: 1225244775) practices hematology/oncology in the Anaheim-Santa Ana-Irvine, CA market, with the plurality of this provider's patient population coming from Orange, CA. This provider's primary affiliated billing organization is CANCER AND BLOOD SPECIALTY CLINIC (NPI: 1538302351; TIN: 264394436) and primary practice location at 92708-5153.

Vu's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 648 traditional Medicare patients, billed 141,089 HCPCS/CPT codes, and received $2,629,967 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 1,776 prescription claims across 265 beneficiaries totaling $8,226,579 in drug costs, led by Tagrisso (Osimertinib Mesylate). DME data shows 133 claims. Open Payments data shows 124 records totaling $3,189. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved from a lower plateau to a higher plateau, from $969,810 to $2,629,967. Similarly, Part D prescription costs have moved sharply higher in recent years, from $1,919,794 to $8,226,579. In contrast, DME billing represents a smaller volume and moved up and down with repeated peaks and valleys, starting at $4,935 and ending at $387.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	347	78,015	$969,810
2016	350	58,992	$1,154,672
2017	333	60,081	$1,286,286
2018	337	58,808	$1,551,385
2019	313	66,016	$1,419,766
2020	410	42,463	$778,064
2021	541	97,538	$1,481,306
2022	551	137,845	$1,917,083
2023	601	121,922	$2,395,778
2024	648	141,089	$2,629,967

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	182	1,197	$1,919,794
2016	190	1,306	$3,013,291
2017	178	1,205	$3,367,348
2018	173	1,313	$3,977,072
2019	154	881	$3,403,087
2020	159	835	$3,635,863
2021	160	933	$3,518,255
2022	196	1,424	$5,746,374
2023	246	1,934	$8,102,878
2024	265	1,776	$8,226,579

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	73	$26,220
2016	N/R	38	$966
2017	N/R	N/R	N/R
2018	N/R	13	$234
2019	N/R	61	$5,136
2020	N/R	24	$429
2021	N/R	71	$6,328
2022	N/R	38	$1,361
2023	14	81	$13,210
2024	25	133	$2,937

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	116	168	$148
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	218	268	$143
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	346	1,316	$103
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	119	221	$66
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	232	1,107	$65

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Tagrisso	Osimertinib Mesylate	48	1,434	$812,012
Verzenio	Abemaciclib	36	1,008	$546,491
Keytruda	Pembrolizumab	39	826	$434,707
Lenvima	Lenvatinib Mesylate	17	510	$413,091
Nubeqa	Darolutamide	30	900	$377,585

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	34	$1,254
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	14	32	$565
J8999	Prescription drug, oral, chemotherapeutic, nos	N	N/R	14	$507
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	11	34	$389
J8520	Capecitabine, oral, 150 mg	N	N/R	19	$223

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	124	$3,189	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Collin Cuong Vu, M.D.?

Tedicare shows public-source Medicare data for Collin Cuong Vu, M.D. (NPI 1225244775), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Collin Cuong Vu, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Collin Cuong Vu, M.D.?

Collin Cuong Vu, M.D. is linked to CANCER AND BLOOD SPECIALTY CLINIC (billing NPI 1538302351) in the available physician profile data.

Does Collin Cuong Vu, M.D. have Open Payments data?

Collin Cuong Vu, M.D. has 124 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.